Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

GSK 1,405.50 +13.50 (0.97%)
price chart
Bonds Resurrected as Glaxo Leads Rising Sales
GlaxoSmithKline Plc (GSK)'s $5 billion offering, its first dollar-denominated sale in more than four years, led issuance of at least $55.1 billion this week following $45.8 billion in the period ended April 27, according to data compiled by Bloomberg.
Related articles »  
GSK partner Pronova wins fish oil drug patent fight
LONDON (Reuters) - Norway's Pronova BioPharma PRON.OL, which supplies the omega-3 heart medicine Lovaza to GlaxoSmithKline (GSK.L), has defeated a U.S. patent challenge from two generics companies, sending Pronova shares 28 percent higher ...
GSK partner Pronova wins Lovaza patent case against Teva & Par Pharma
Pronova Defeats Teva, Par In Lovaza Patent Suit  Law360 (subscription)
Related articles »  
GlaxoSmithKline 'avoided corporation tax bill of �34m', according to BBC
Tesco Plc. CEO Dave Lewis arrives for Tesco's interim results announcement in London October 23 RUTH SUNDERLAND Why FTSE 100 bosses have to get a grip on reality; ALEX BRUMMER Bid for Heathrow mastery as British Airways targets Aer Lingus ...
Related articles »  
Glaxo to Begin Hostile Offer for Human Genome Sciences
Glaxo's bid is part of a wave of takeover activity in the pharmaceutical industry as drugmakers seek new products. Roche Holding AG (ROG) made a hostile offer for Illumina Inc. in January, and abandoned it last month.
Related articles »  
Glaxo's Melanoma Cocktail Slows Cancer in Study
GlaxoSmithKline Plc (GSK)'s combination of two experimental melanoma medicines slowed the progress of cancer with few skin complications in an early study, suggesting the combo may not have as many side effects as existing single-drug treatments.
Dabrafenib And Trametinib: Melanoma Drug Combo Shows Promise In Small Trial  Huffington Post
ASCO: Dabrafenib/Trametinib active in metastatic melanoma  Medical Xpress
Related articles »  
Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover
GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI:US), its partner on the drug.
Related articles »  
Germany joins UK in spurning GSK's new lupus drug
The drug, which was discovered by Human Genome and developed with GSK to combat a disease that causes the immune system to attack joints and organs, is at the centre of a $2.6 billion takeover bid by GSK for its U.S. biotech partner. GSK, Britain's ...
Related articles »  
GlaxoSmithKline Launches Hostile Takeover Bid for Human Genome Sciences
GlaxoSmithKline Plc (NYSE: GSK), Britain's biggest drugmaker, will mount a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (NASDAQ: HGSI), the company announced Wednesday.
Related articles »  
GSK Says La. Can't Use Outside Attys In $12B Avandia Suit
Law360, New York (May 31, 2012, 4:30 PM ET) -- GlaxoSmithKline PLC urged a Louisiana state court on Thursday to bar the state's attorney general from using private attorneys to pursue a $12 billion Medicaid fraud suit over the safety risks of diabetes ...
GSK pays 61 million pounds to take control of Cellzome
GSK said on Tuesday that it hoped that Cellzome's technology, which assesses drug interactions with target proteins in a setting that mimics the body's biology, would reduce the number of medicines that fail during development.
Drugs giant GSK to take full control of Cambridge-based Cellzome
Related articles »